HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Contaminated Eye Drops Return To US FDA’s View

Executive Summary

FDA says FivFivGo, Rebright and South Moon are copycats in packaging easily mistaken for Lumify OTC eye drops. Testing found South Moon contaminated with bacteria linked to an antibiotic-resistant infection; agency warns using any of the three poses risk of eye infection.

You may also be interested in...

US FDA Revises Draft Guidance On Eye Drops Quality With Microbiology Topics Section

Bicom California suggests FDA add a section on microbiology-related topics relevant to ophthalmic products, which include OTC monograph drugs and Rx and nonprescription formulations available through approved applications.

Second Indian Firm's Eye Drops Recalled In US

All lots of nearly 30 different dry eye and lubricating products made by Mumbai-based Kilitch Healthcare India and sold in US by major drug store chains and marketed under multiple private label brands are recalled after FDA investigators found insanitary conditions at firm’s facility.

‘Pervasive Contamination’ Found At Indian Eye Drop Firm Linked To Antibiotic-Resistant Infections

FDA also responds to sting OTC eye drop sector felt with warnings to Amazon after investigators purchased drops labeled with violative claims and a natural health care products firm with Amazon storefront offering drops with ingredient commonly used in joint health supplements and claims to “soften the membranes of the eye.”

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts